STRO — SUTRO BIOPHARMA, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1382101 ·
Last close
$15.98
Market Cap
$264.97M
52W High
$43.85
52W Low
$7.15
ADV30
299,733
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 9,839,000 — -29,687,000 -38,533,000 194,462,000 54,335,000 297,779,000
Mar 2026 14,523,000 — -29,614,000 -38,484,000 241,988,000 73,682,000 308,875,000
Dec 2025 11,647,000 — -33,657,000 -46,762,000 173,830,000 58,130,000 306,282,000
Sep 2025 9,693,000 — -38,901,000 -56,857,000 209,658,000 65,927,000 296,926,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-151,607,000
Investing CF
$16,007,000
Financing CF
$103,053,000
CapEx
$-532,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-20.12
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,016,439,000
Inventory
—
Receivables
$12,484,000
ST Investments
$128,876,000
EBIT TTM
$-111,812,000
Pretax Income TTM
$-153,717,000
Interest Exp TTM
$41,905,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$45,702,000
EBITDA
$-125,795,000
Free Cash Flow
$-100,756,000
Enterprise Value
$125,995,544
Total Cash
$164,346,000
Total Debt
$10,783,000
Shares Out
16,581,171
Trailing EPS
$-17.37
Book Value
$-6.23
ROE
—
ROA
-36.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 102,484,000 -104,952,000 -191,086,000 173,830,000 306,282,000 -132,452,000 -177,231,000
Dec 2024 62,043,000 -238,453,000 -227,461,000 387,207,000 342,606,000 44,601,000 -191,540,000
Dec 2023 153,731,000 -89,278,000 -106,793,000 470,736,000 321,087,000 149,649,000 -111,616,000
Dec 2022 67,772,000 -128,943,000 -119,204,000 406,944,000 189,896,000 217,048,000 3,549,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.21

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $17.50 · spot: $15.44 · call volume: 20 · put volume: 4

Peers — same industry

TickerNameMarket CapLastDaily %
LCTX Lineage Cell Therapeutics, Inc. $260.49M $1.03 —
LXEO Lexeo Therapeutics, Inc. $271.57M $3.31 —
IVVD Invivyd, Inc. $275.30M $0.93 —
PALI PALISADE BIO, INC. $252.69M $1.45 —
FATE FATE THERAPEUTICS INC $281.58M $2.35 —

News headlines (Yahoo Finance, 1h cache)

STRO Stock Plummets 15% — What Drove The Selloff?
2026-08-12 20:07 · Yahoo
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
2026-08-12 11:00 · Yahoo
News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
2026-05-28 11:19 · Yahoo
US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results
2026-05-17 13:02 · Yahoo
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-14 20:05 · Yahoo
Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program
2026-05-01 08:17 · Yahoo
Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now
2026-04-29 17:00 · Yahoo
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
2026-04-19 23:45 · Yahoo
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 12:35 · Yahoo
Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More
2026-08-07 11:51 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.